Trial Profile
A Pilot Study of Eniluracil Containing Ointment for Prevention of Hand Foot Syndrome (HRS) Following Capecitabine (Xeloda)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 01 Jun 2018
Price :
$35
*
At a glance
- Drugs Eniluracil (Primary)
- Indications Erythrodysaesthesia
- Focus Adverse reactions; Therapeutic Use
- 25 May 2018 Status changed to discontinued.
- 09 Apr 2014 New trial record